CN115894207A - Synthesis method of 2- (3-hydroxy-1-adamantane) -2-oxoacetic acid - Google Patents
Synthesis method of 2- (3-hydroxy-1-adamantane) -2-oxoacetic acid Download PDFInfo
- Publication number
- CN115894207A CN115894207A CN202211573194.5A CN202211573194A CN115894207A CN 115894207 A CN115894207 A CN 115894207A CN 202211573194 A CN202211573194 A CN 202211573194A CN 115894207 A CN115894207 A CN 115894207A
- Authority
- CN
- China
- Prior art keywords
- adamantane
- acid
- hydroxy
- oxoacetic acid
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001308 synthesis method Methods 0.000 title claims abstract description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000007864 aqueous solution Substances 0.000 claims abstract description 12
- 239000007818 Grignard reagent Substances 0.000 claims abstract description 9
- 150000004795 grignard reagents Chemical class 0.000 claims abstract description 9
- VQHPRVYDKRESCL-UHFFFAOYSA-N 1-bromoadamantane Chemical compound C1C(C2)CC3CC2CC1(Br)C3 VQHPRVYDKRESCL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000002253 acid Substances 0.000 claims abstract description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims abstract description 7
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910017604 nitric acid Inorganic materials 0.000 claims abstract description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 5
- 230000002378 acidificating effect Effects 0.000 claims abstract description 5
- 239000012286 potassium permanganate Substances 0.000 claims abstract description 5
- 239000012046 mixed solvent Substances 0.000 claims abstract description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- 238000010189 synthetic method Methods 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 230000003301 hydrolyzing effect Effects 0.000 claims description 3
- 239000007810 chemical reaction solvent Substances 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims 6
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims 3
- -1 adamantane keto acid Chemical class 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- RGWHHWWMFUXNAX-UHFFFAOYSA-N bis(1-adamantyl)methanone Chemical compound C1C(C2)CC(C3)CC2CC13C(=O)C1(C2)CC(C3)CC2CC3C1 RGWHHWWMFUXNAX-UHFFFAOYSA-N 0.000 abstract description 5
- 239000011777 magnesium Substances 0.000 abstract description 4
- 229910052749 magnesium Inorganic materials 0.000 abstract description 3
- 229910052751 metal Inorganic materials 0.000 abstract description 3
- 239000002184 metal Substances 0.000 abstract description 3
- IYKFYARMMIESOX-SPJNRGJMSA-N adamantanone Chemical compound C([C@H](C1)C2)[C@H]3C[C@@H]1C(=O)[C@@H]2C3 IYKFYARMMIESOX-SPJNRGJMSA-N 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 5
- 108010033693 saxagliptin Proteins 0.000 description 4
- UDKIRRNUAXWHTO-UHFFFAOYSA-N 2-(3-hydroxy-1-adamantyl)-2-oxoacetic acid Chemical compound C1C(C2)CC3CC2(O)CC1(C(=O)C(=O)O)C3 UDKIRRNUAXWHTO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 229960004937 saxagliptin Drugs 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- DACIGVIOAFXPHW-UHFFFAOYSA-N 1-(1-adamantyl)ethanone Chemical compound C1C(C2)CC3CC2CC1(C(=O)C)C3 DACIGVIOAFXPHW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- MIBQYWIOHFTKHD-UHFFFAOYSA-N adamantane-1-carbonyl chloride Chemical compound C1C(C2)CC3CC2CC1(C(=O)Cl)C3 MIBQYWIOHFTKHD-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940001450 onglyza Drugs 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种2‑(3‑羟基‑1‑金刚烷)‑2‑氧代乙酸的合成方法,具体的包括以下步骤:步骤1:溴代金刚烷和金属镁反应生成格氏试剂;步骤2:格氏试剂和乙腈反应,再在酸性水溶液中水解得到1‑金刚烷甲酮;步骤3:1‑金刚烷甲酮用高锰酸钾在碱性水溶液中氧化得到金刚烷酮酸;步骤4:金刚烷酮酸在浓硝酸和浓硫酸的混合溶剂中反应后水解得到2‑(3‑羟基‑1‑金刚烷)‑2‑氧代乙酸。本发明的一种2‑(3‑羟基‑1‑金刚烷)‑2‑氧代乙酸的合成方法步骤较少,收率高,原料简单易得,合成方法操作简单。The invention discloses a synthesis method of 2-(3-hydroxyl-1-adamantane)-2-oxoacetic acid, specifically comprising the following steps: Step 1: reacting bromoadamantane and metal magnesium to generate Grignard reagent; Step 2: Grignard reagent reacts with acetonitrile, and then hydrolyzes in acidic aqueous solution to obtain 1-adamantanyl ketone; Step 3: 1-adamantanyl ketone is oxidized with potassium permanganate in alkaline aqueous solution to obtain adamantanonic acid; Step 4: adamantanone acid is reacted in a mixed solvent of concentrated nitric acid and concentrated sulfuric acid and then hydrolyzed to obtain 2-(3-hydroxyl-1-adamantane)-2-oxoacetic acid. The synthesis method of 2-(3-hydroxyl-1-adamantane)-2-oxoacetic acid of the present invention has fewer steps, high yield, simple and easy-to-obtain raw materials, and simple operation of the synthesis method.
Description
技术领域technical field
本发明涉及医药中间体合成技术领域,具体涉及一种2-(3-羟基-1-金刚烷)-2-氧代乙酸的合成方法。The invention relates to the technical field of synthesis of pharmaceutical intermediates, in particular to a synthesis method of 2-(3-hydroxy-1-adamantane)-2-oxoacetic acid.
背景技术Background technique
沙格列汀(saxagliptin),商品名Onglyza,化学名为(1S,3S,5S)-2-[(2S)-2-氨基-2-(3-羟基三环[3.3.1.13,7]癸-1-基)乙酰基]-2-氮杂双环[3.1.0]-己烷-3-腈,由Bristol-Myers Squibb公司与AstraZeneca公司联合开发,2009年7月经FDA批准上市。沙克列汀是一种高选择性、可逆性的竞争性二肽基肽酶Ⅳ(DPP-Ⅳ)抑制剂,耐受性好且不引起肥胖,临床用于治疗Ⅱ型糖尿病。Saxagliptin, trade name Onglyza, chemical name (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]decane -1-yl)acetyl]-2-azabicyclo[3.1.0]-hexane-3-carbonitrile, jointly developed by Bristol-Myers Squibb and AstraZeneca, approved by FDA in July 2009. Saxagliptin is a highly selective and reversible competitive dipeptidyl peptidase Ⅳ (DPP-Ⅳ) inhibitor, which is well tolerated and does not cause obesity. It is clinically used for the treatment of type Ⅱ diabetes.
2-(3-羟基-1-金刚烷基)-2-氧代乙酸是合成沙格列汀的重要中间体,CAS登记号为:709031-28-7,其结构式为:2-(3-Hydroxy-1-adamantyl)-2-oxoacetic acid is an important intermediate for the synthesis of saxagliptin, the CAS registration number is: 709031-28-7, and its structural formula is:
Letters in Organic Chemistry,2012,9(5),347-350将制备得到的金刚烷甲酰氯与丙二酸二乙酯的钠盐反应后,水解脱羧得乙酰金刚烷,再经高锰酸钾氧化、羟基化得到2-(3-羟基-1-金刚烷基)-2-氧代乙酸;Letters in Organic Chemistry, 2012, 9(5), 347-350 reacts the prepared adamantanecarbonyl chloride with the sodium salt of diethyl malonate, hydrolyzes and decarboxylates to obtain acetyladamantane, and then oxidizes it with potassium permanganate , hydroxylation to obtain 2-(3-hydroxyl-1-adamantyl)-2-oxoacetic acid;
其中,合成乙酰金刚烷需要三步反应,路线较长,产率较低。Among them, the synthesis of acetyladamantane requires three steps of reaction, the route is longer and the yield is lower.
发明内容Contents of the invention
1.所要解决的技术问题:1. Technical problems to be solved:
针对上述技术问题,本发明提供一种2-(3-羟基-1-金刚烷)-2-氧代乙酸的合成方法。In view of the above technical problems, the present invention provides a synthetic method of 2-(3-hydroxy-1-adamantane)-2-oxoacetic acid.
2.技术方案:2. Technical solution:
一种2-(3-羟基-1-金刚烷)-2-氧代乙酸的合成方法,所述合成方法的路线如下:A kind of synthetic method of 2-(3-hydroxyl-1-adamantane)-2-oxoacetic acid, the route of described synthetic method is as follows:
具体的包括以下步骤:Specifically, the following steps are included:
步骤1:溴代金刚烷和金属镁反应生成格氏试剂;Step 1: bromoadamantane reacts with metal magnesium to generate Grignard reagent;
步骤2:格氏试剂和乙腈反应,再在酸性水溶液中水解得到1-金刚烷甲酮;Step 2: Grignard reagent reacts with acetonitrile, and then hydrolyzes in acidic aqueous solution to obtain 1-adamantanyl ketone;
步骤3:1-金刚烷甲酮用高锰酸钾在碱性水溶液中氧化得到金刚烷酮酸;Step 3: 1-adamantanone ketone is oxidized with potassium permanganate in alkaline aqueous solution to obtain adamantanonic acid;
步骤4:金刚烷酮酸在浓硝酸和浓硫酸的混合溶剂中反应后水解得到2-(3-羟基-1-金刚烷)-2-氧代乙酸。Step 4: reacting adamantanone acid in a mixed solvent of concentrated nitric acid and concentrated sulfuric acid and then hydrolyzing it to obtain 2-(3-hydroxy-1-adamantane)-2-oxoacetic acid.
进一步地,步骤1的反应溶剂为四氢呋喃或者乙醚。Further, the reaction solvent in step 1 is tetrahydrofuran or diethyl ether.
进一步地,步骤1的溴代金刚烷和金属镁的摩尔比为1:1.1-1.3。Further, the molar ratio of bromoadamantane and metal magnesium in step 1 is 1:1.1-1.3.
进一步地,步骤2的乙腈和步骤1的溴代金刚烷的摩尔比为1.5-3:1。Further, the molar ratio of the acetonitrile in step 2 to the bromoadamantane in step 1 is 1.5-3:1.
进一步地,步骤2的酸性水溶液为稀盐酸。Further, the acidic aqueous solution in step 2 is dilute hydrochloric acid.
进一步地,步骤3中还可以加入叔丁醇作为助溶剂。Further, in step 3, tert-butanol can also be added as a cosolvent.
进一步地,步骤3的碱性水溶液为氢氧化钠或者氢氧化钾的水溶液。Further, the alkaline aqueous solution in step 3 is an aqueous solution of sodium hydroxide or potassium hydroxide.
进一步地,步骤4的浓硝酸和浓硫酸的体积比为1:10-15。Further, the volume ratio of concentrated nitric acid and concentrated sulfuric acid in step 4 is 1:10-15.
3.有益效果:3. Beneficial effects:
本发明的一种2-(3-羟基-1-金刚烷)-2-氧代乙酸的合成方法步骤较少,收率高,原料简单易得,合成方法操作简单。The synthesis method of 2-(3-hydroxyl-1-adamantane)-2-oxoacetic acid of the present invention has fewer steps, high yield, simple and easy-to-obtain raw materials, and simple operation of the synthesis method.
具体实施方式Detailed ways
下面对本发明进行具体的说明。The present invention will be specifically described below.
实施例1Example 1
一种2-(3-羟基-1-金刚烷)-2-氧代乙酸的合成方法,包括以下步骤:A kind of synthetic method of 2-(3-hydroxyl-1-adamantane)-2-oxoacetic acid, comprises the following steps:
步骤1:将Mg(1.3g,53.5mmol)加入干燥的四氢呋喃(10mL)中,氮气保护下,按照常规格氏试剂制备引发后,剧烈搅拌,升温至40℃,将溴代金刚烷(10g,46.5mmol)溶解在干燥的四氢呋喃(100mL),滴加至该溶液中,期间形成弱回流,滴加完毕后,回流反应1h,冷至室温,形成格氏试剂四氢呋喃溶液。Step 1: Add Mg (1.3g, 53.5mmol) into dry tetrahydrofuran (10mL), under the protection of nitrogen, prepare according to the conventional Grignard reagent, stir vigorously, heat up to 40°C, and bromoadamantane (10g, 46.5mmol) was dissolved in dry tetrahydrofuran (100mL), and added dropwise to the solution, during which a weak reflux was formed. After the dropwise addition, the solution was refluxed for 1h and cooled to room temperature to form a Grignard reagent tetrahydrofuran solution.
步骤2:干燥的乙腈(3.8g,92.6mmol)用四氢呋喃40ml稀释,冷却到-68℃,将步骤1制备的格氏试剂慢慢滴加到该溶液中,滴加时间控制在2h,滴加结束后继续在此温度下反应4h,慢慢滴加2mol/L稀盐酸至pH至7以下,继续搅拌1h。减压浓缩除去部分四氢呋喃,用乙酸乙酯50ml萃取三次,合并有机相,有机相用饱和食盐水洗涤,用无水硫酸钠干燥后,过滤,浓缩,粗品用二氯甲烷:正己烷(1:10)结晶纯化,得到1-金刚烷甲酮(7.2g,40.4mmol),步骤1-2两步收率为86.9%。Step 2: Dried acetonitrile (3.8g, 92.6mmol) was diluted with 40ml of tetrahydrofuran, cooled to -68°C, and the Grignard reagent prepared in step 1 was slowly added dropwise to the solution, and the dropping time was controlled at 2h. After the end, continue to react at this temperature for 4 hours, slowly add 2 mol/L dilute hydrochloric acid dropwise until the pH is below 7, and continue stirring for 1 hour. Concentrate under reduced pressure to remove part of tetrahydrofuran, extract three times with 50 ml of ethyl acetate, combine the organic phases, wash the organic phase with saturated brine, dry with anhydrous sodium sulfate, filter, concentrate, and dichloromethane: n-hexane (1: 10) Purification by crystallization to obtain 1-adamantanyl ketone (7.2 g, 40.4 mmol), the yield of step 1-2 is 86.9%.
步骤3:在1-金刚烷甲酮(5.0g,28mmol)中加入100ml 2%KOH溶液,20ml叔丁醇,加热至40℃,1小时内分批加入高锰酸钾(8g,50.6mmol),保持40℃反应5个小时,加入20mL10%亚硫酸钠溶液淬灭反应。趁热抽滤,滤饼用15ml热水洗涤。滤液冷却至室温,用浓盐酸调到pH=1,乙酸乙酯萃取三次,合并有机层用饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩至油状物,用乙酸乙酯∶正己烷(1∶1)结晶得金刚烷酮酸的白色固体5.3g,收率90.74%。Step 3: Add 100ml 2% KOH solution, 20ml tert-butanol to 1-adamantanyl ketone (5.0g, 28mmol), heat to 40°C, add potassium permanganate (8g, 50.6mmol) in batches within 1 hour , kept at 40° C. for 5 hours, and added 20 mL of 10% sodium sulfite solution to quench the reaction. Suction filtration while hot, and the filter cake was washed with 15ml of hot water. The filtrate was cooled to room temperature, adjusted to pH = 1 with concentrated hydrochloric acid, extracted three times with ethyl acetate, the combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure to an oil, and washed with ethyl acetate: n-hexane ( 1:1) crystallization to obtain 5.3 g of white solid of adamantanonic acid, yield 90.74%.
步骤4:在0℃~5℃下,将金刚烷酮酸(5g,24mmol)分批加入65%硝酸(2.5mL)和95%硫酸(27mL)的混合物中,保持温度不高于25℃。然后室温反应3小时,反应液变为深黄色,将此反应混合物倒入冰水,用乙酸乙酯萃取有机层(50mL×3)。合并有机层并用饱和食盐水洗,浓缩得到粗品,粗品用乙酸乙酯:正己烷(1:3)重结晶,得到2-(3-羟基-1-金刚烷)-2-氧代乙酸(4.0g,17.8mmol),收率74.3%。Step 4: Add adamantanonic acid (5 g, 24 mmol) in batches to a mixture of 65% nitric acid (2.5 mL) and 95% sulfuric acid (27 mL) at 0°C to 5°C, keeping the temperature not higher than 25°C. Then reacted at room temperature for 3 hours, and the reaction solution turned dark yellow. The reaction mixture was poured into ice water, and the organic layer was extracted with ethyl acetate (50 mL×3). The organic layers were combined and washed with saturated brine, and concentrated to obtain a crude product, which was recrystallized from ethyl acetate:n-hexane (1:3) to obtain 2-(3-hydroxy-1-adamantane)-2-oxoacetic acid (4.0g , 17.8mmol), yield 74.3%.
虽然本发明已以较佳实施例公开如上,但它们并不是用来限定本发明的,任何熟习此技艺者,在不脱离本发明之精神和范围内,自当可作各种变化或润饰,因此本发明的保护范围应当以本申请的权利要求保护范围所界定的为准。Although the present invention has been disclosed as above with preferred embodiments, they are not intended to limit the present invention. Any skilled person can make various changes or modifications without departing from the spirit and scope of the present invention. Therefore, the protection scope of the present invention should be defined by the protection scope of the claims of the present application.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211573194.5A CN115894207B (en) | 2022-12-08 | 2022-12-08 | A method for synthesizing 2-(3-hydroxy-1-adamantane)-2-oxoacetic acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211573194.5A CN115894207B (en) | 2022-12-08 | 2022-12-08 | A method for synthesizing 2-(3-hydroxy-1-adamantane)-2-oxoacetic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115894207A true CN115894207A (en) | 2023-04-04 |
| CN115894207B CN115894207B (en) | 2025-05-02 |
Family
ID=86470955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211573194.5A Active CN115894207B (en) | 2022-12-08 | 2022-12-08 | A method for synthesizing 2-(3-hydroxy-1-adamantane)-2-oxoacetic acid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115894207B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012028721A1 (en) * | 2010-09-03 | 2012-03-08 | Sandoz Ag | PROCESS FOR THE REDUCTIVE AMINATION OF α-KETO CARBOXYLIC ACIDS |
| CN102807487A (en) * | 2012-09-03 | 2012-12-05 | 方正 | Synthetic method of onglyza intermediate |
| CN114621068A (en) * | 2022-03-31 | 2022-06-14 | 沧州那瑞化学科技有限公司 | Preparation method of 3-hydroxy-1-adamantane methyl ketone and method for synthesizing saxagliptin |
-
2022
- 2022-12-08 CN CN202211573194.5A patent/CN115894207B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012028721A1 (en) * | 2010-09-03 | 2012-03-08 | Sandoz Ag | PROCESS FOR THE REDUCTIVE AMINATION OF α-KETO CARBOXYLIC ACIDS |
| CN102807487A (en) * | 2012-09-03 | 2012-12-05 | 方正 | Synthetic method of onglyza intermediate |
| CN114621068A (en) * | 2022-03-31 | 2022-06-14 | 沧州那瑞化学科技有限公司 | Preparation method of 3-hydroxy-1-adamantane methyl ketone and method for synthesizing saxagliptin |
Non-Patent Citations (5)
| Title |
|---|
| ANMIN WANG, ET AL.: "A Convenient Method for the Synthesis of (S)-N-boc-3-hydroxyadamantyl- glycine: A Key Intermediate of Saxagliptin", 《LETTERS IN ORGANIC CHEMISTRY》, vol. 11, 31 December 2014 (2014-12-31), pages 627 - 631 * |
| DAVID GRASSI, ET AL.: "Formation of chiral fluoroalkyl products through copper-free enantioselective allylic alkylation catalyzed by an NHC ligand", 《CHEM. COMMUN.》, vol. 48, 3 October 2012 (2012-10-03), pages 11404 - 11406 * |
| YURCHENKO, A. G. AND FEDORENKO, T. V.: "Reaction of adamantanoid organomagnesium compounds with carbonyl compounds", 《ZHURNAL ORGANICHESKOI KHIMII》, vol. 23, no. 5, 31 December 1987 (1987-12-31), pages 970 - 976 * |
| 冯悦 等: "星点设计-效应面优化法优化2-(3-羟基-1-金刚烷基)-2-乙醛酸的合成工艺", 《化学研究与应用》, vol. 25, no. 2, 28 February 2013 (2013-02-28), pages 194 - 199 * |
| 王安民 等: "N-叔丁氧羰基-3-羟基-1-金刚烷基甘氨酸的合成", 《化学研究与应用》, vol. 26, no. 4, 30 April 2014 (2014-04-30), pages 527 - 531 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115894207B (en) | 2025-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104761456B (en) | Preparation method of 3-amino-1-adamantanol | |
| CN104262359A (en) | Synthetic method of salbactam acid | |
| WO2023060811A1 (en) | Fluralaner intermediate and method for preparing fluralaner thereby | |
| CN112898307A (en) | Ketorolac impurity C and preparation method and application thereof | |
| CN105732444A (en) | Synthesis method of belinostat | |
| CN102267961B (en) | Method for preparing ethyl (3R,4R,5S)-4,5-epoxy-3-(1-ethyl-propoxy)-1-cyclohexene-1-formate | |
| JPS6222740A (en) | Isolation of p-hydroxybenzaldehyde | |
| CN115894207A (en) | Synthesis method of 2- (3-hydroxy-1-adamantane) -2-oxoacetic acid | |
| CN108440409B (en) | Green and efficient preparation method of rebamipide | |
| JP4450881B2 (en) | Process for producing 5,5'-bi-1H-tetrazole salt | |
| CN102485722B (en) | Aliskiren, its intermediates and medicinal salt, as well as preparation method thereof | |
| WO2005110962A1 (en) | Process for producing adipic acid | |
| CN111440079B (en) | A kind of synthetic method of DL-threo-p-chlorophenylserine | |
| US12448360B2 (en) | Synthesis method for preparing SGLT inhibitor intermediate | |
| CN115124452A (en) | Preparation method of 2- (4-amino-2-ethoxyphenyl) isoindole-1, 3-dione | |
| CN114044770B (en) | Method for removing pigment impurities of sartan compounds in water phase | |
| CN108137485A (en) | The preparation method of benzoic acid amide compound | |
| CN115417794B (en) | Preparation method of saxagliptin intermediate | |
| CN117510567B (en) | A method for preparing high-purity alfaxalone | |
| CN112661688B (en) | Synthetic method of non-steroidal anti-inflammatory drug tolmetin | |
| CN109384701A (en) | It is a kind of to be used to prepare compound and the preparation method and application thereof of the Sha Ku than song | |
| CN116924919A (en) | Synthesis method of N- (2-methoxyethyl) ethylamine | |
| CN117126101A (en) | An efficient preparation method of proline structure hydrochloride intermediate | |
| CN118851972A (en) | A method for industrial preparation of antiviral ketoamide derivative intermediates | |
| CN111620892A (en) | Method for synthesizing sulbactam acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |







